The rejection of the evergreen provision signals shareholder restraint on automatic dilution, but the approved share increase provides ample near-term equity for compensation. Monitor future proxy filings for any new equity plan proposals or changes in compensation strategy.
Price Chart
Executive Summary
OptimizeRx held its 2026 Annual Meeting on June 9, 2026. Shareholders approved an amendment to the 2021 Equity Incentive Plan to increase the share reserve by 1,000,000 shares to 5,450,000 shares, but rejected a proposed evergreen provision that would have allowed automatic annual increases. All seven director nominees were elected, and Grant Thornton LLP was ratified as auditor. The rejection of the evergreen provision, following a prior DEFA14A solicitation urging support, is a modest governance check but does not materially alter the company's equity compensation capacity.
Key Facts
- Shareholders approved increasing the equity plan share reserve by 1,000,000 shares to 5,450,000 shares.
- Shareholders rejected the evergreen provision (5,627,324 for, 7,001,699 against) that would have allowed automatic annual increases of up to 5% of outstanding shares through 2031.
- All seven director nominees were elected; Stephen Silvestro received the most votes (12,160,558 for).
- Advisory vote on executive compensation passed with 11,660,549 votes in favor.
- Grant Thornton LLP was ratified as independent auditor for fiscal 2026 with 15,750,329 votes in favor.
- Record date was April 10, 2026, with 18,765,075 shares outstanding and entitled to vote.
Financial Impact
Equity plan share pool increased by 1,000,000 shares (approximately 5.3% of current outstanding shares of 18,765,075). No cash impact.
Risk Factors
- Potential future dilution if the full 1,000,000 share increase is awarded and exercised.
- Shareholder pushback on equity compensation may constrain talent retention if the company needs to issue more shares than approved.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-068272 |
| Document: ea029456501ex10-1.htm | 0001213900-26-068272 |
| Document: 0001213900-26-068272-index-headers.html | 0001213900-26-068272 |
| Document: 0001213900-26-068272-index.html | 0001213900-26-068272 |
| Document: 0001213900-26-068272.txt | 0001213900-26-068272 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | SC 13G/A | $9.37 | awaiting T+20 | — | $9.07 (−3.20%) |
Sep 22, 2026 4w ago | Institutional Cluster | $7.62 $8.93 | ▲ +17.19% | ▲ +17.75% | $9.07 (+19.03%) |
Aug 12, 2026 10w ago | Press Release | $8.78 $7.29 | ▼ −16.97% | ▼ −15.22% | $9.07 (+3.30%) |
Jun 12, 2026 19w ago | 8-K | $5.32 $6.55 | ▲ +23.12% | ▲ +23.87% | $9.07 (+70.49%) |
Jun 11, 2026 19w ago | Institutional Cluster | $5.28 $6.28 | ▲ +18.94% | ▲ +17.05% | $9.07 (+71.78%) |
Jun 5, 2026 20w ago | 8-K | $5.05 $6.35 | ▲ +25.74% | ▲ +24.11% | $9.07 (+79.60%) |
Jun 1, 2026 21w ago | DEFA14A | $5.38 $5.72 | ▲ +6.32% | ▲ +7.62% | $9.07 (+68.59%) |
May 21, 2026 22w ago | Press Release | $4.94 $4.70 | ▼ −4.86% | ▼ −5.19% | $9.07 (+83.60%) |
May 12, 2026 23w ago | Press Release | $4.92 $5.28 | ▲ +7.32% | ▲ +7.93% | $9.07 (+84.35%) |
Mar 5, 2026 33w ago | Press Release | $6.74 $6.80 | ▲ +0.89% | ▲ +2.93% | $9.07 (+34.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers